New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
06:41 EDTJNJSurgeon told by J&J sales rep of hip implant troubles, Bloomberg reports
A surgeon in Montana testified that he stopped using Johnson & Johnsonís (JNJ) ASR all-metal hip device eight months before the company recalled it because a sales rep warned about problems with the implant by, reports Bloomberg. Peter Wendt, testified that he implanted 76 ASRs, including one in Loren Kransky, 65, of Montana. Kranskyís lawsuit is the first of 10,000 to go to trial over claims that J&Jís DePuy unit defectively designed the 93,000 hips recalled in August 2010 and failed to warn of the risks. J&J, denies that it defectively designed the device or that it contributed to the health problems of Kransky. Reference Link
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent JNJ news | >>
May 28, 2015
08:04 EDTJNJCardinal Health confirms binding offer to acquire Cordis accepted from JNJ
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson accepts binding offer from Cardinal Health to acquire Cordis
Subscribe for More Information
May 27, 2015
13:28 EDTJNJFBI investigating Johnson & Johnson over discontinued surgical tool, WSJ says
The FBI is investigating Johnson & Johnson over whether it knew about the potential hazards of a surgical device known as a laparoscopic power morcellator before the device was pulled from the market in 2014, reports The Wall Street Journal, citing three people with knowledge of the matter. The Journal notes that the U.S. FDA recommended a "black box" warning for the device in November, stating that it should not be used on the "vast majority" of women because morcellators can spread malignant cancer and worsen patient outcomes. Reference Link
13:10 EDTJNJJ&J being probed by FBI over discontinued surgical device, DJ reports
Subscribe for More Information
May 26, 2015
08:14 EDTJNJBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 22, 2015
10:52 EDTJNJJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
08:17 EDTJNJJohnson & Johnson reports STELARA receives CHMP positive opinion
Janssen-Cilag announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending approval for the use of STELARA for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
May 21, 2015
17:08 EDTJNJJohnson & Johnson Chief Accounting Officer Stephen Cosgrove to retire in October
Subscribe for More Information
May 20, 2015
16:26 EDTJNJOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
10:26 EDTJNJJanssen acquires licence from Novo Nordisk for autoimmune disease development
Novo Nordisk (NVO) announced it has signed an agreement with Janssen Biotech (JNJ) under which Janssen will acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor, specifically the NKG2D receptor. Terms of the agreement have not been disclosed.
09:07 EDTJNJJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
08:49 EDTJNJJohnson & Johnson: Priorities for free cash flow include dividends, repurchases
Subscribe for More Information
08:30 EDTJNJAchillion price target lowered to $16 from $25 at Leerink
Leerink says Achillion's deal with Johnson & Johnson (JNJ) increases the probability that it will be a competitive commercial-stage player in hepatitis C. The firm believes the collaboration limits share downside as well as upside by making the "home-run scenario of great combo data leading to an acquisition less likely." It lowered its price target for Achillion shares to $16 and keeps an Outperform rating on the name.
08:15 EDTJNJJohnson & Johnson CEO Alex Gorsky says won't pursue pure-play strategy
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson to hold a meeting
Subscribe for More Information
07:51 EDTJNJAchillion shares remain undervalued after HCV pact with J&J, says Cowen
Subscribe for More Information
07:33 EDTJNJJ&J to file more than 10 new '$1B potenital' products by 2019
Subscribe for More Information
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation Ė JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
1 | 2 | all recent JNJ news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use